Literature DB >> 29660395

Endogenous PGI2 signaling through IP inhibits neutrophilic lung inflammation in LPS-induced acute lung injury mice model.

Shinji Toki1, Weisong Zhou1, Kasia Goleniewska1, Sara Reiss1, Daniel E Dulek1, Dawn C Newcomb1, William E Lawson1, R Stokes Peebles2.   

Abstract

Endogenous prostaglandin I2 (PGI2) has inhibitory effects on immune responses against pathogens or allergens; however, the immunomodulatory activity of endogenous PGI2 signaling in endotoxin-induced inflammation is unknown. To test the hypothesis that endogenous PGI2 down-regulates endotoxin-induced lung inflammation, C57BL/6 wild type (WT) and PGI2 receptor (IP) KO mice were challenged intranasally with LPS. Urine 6-keto-PGF1α, a stable metabolite of PGI2, was significantly increased following the LPS-challenge, suggesting that endogenous PGI2 signaling modulates the host response to LPS-challenge. IPKO mice had a significant increase in neutrophils in the BAL fluid as well as increased proteins of KC, LIX, and TNF-α in lung homogenates compared with WT mice. In contrast, IL-10 was decreased in LPS-challenged IPKO mice compared with WT mice. The PGI2 analog cicaprost significantly decreased LPS-induced KC, and TNF-α, but increased IL-10 and AREG in bone marrow-derived dendritic cells (BMDCs) and bone marrow-derived macrophages (BMMs) compared with vehicle-treatment. These results indicated that endogenous PGI2 signaling attenuated neutrophilic lung inflammation through the reduced inflammatory cytokine and chemokine and enhanced IL-10. Published by Elsevier Inc.

Entities:  

Keywords:  Acute lung injury; Cicaprost; Neutrophil; Prostaglandin I(2)

Mesh:

Substances:

Year:  2018        PMID: 29660395      PMCID: PMC5970997          DOI: 10.1016/j.prostaglandins.2018.04.001

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  49 in total

Review 1.  Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs.

Authors:  Zeenat Safdar
Journal:  Respir Med       Date:  2011-01-26       Impact factor: 3.415

2.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

Review 3.  How neutrophils kill microbes.

Authors:  Anthony W Segal
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

4.  Incidence and outcomes of acute lung injury.

Authors:  Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

6.  Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation.

Authors:  Anna A Birukova; Tatiana Zagranichnaya; Panfeng Fu; Elena Alekseeva; Weiguo Chen; Jeffrey R Jacobson; Konstantin G Birukov
Journal:  Exp Cell Res       Date:  2007-04-06       Impact factor: 3.905

7.  Polymorphism of the promoter region of prostacyclin synthase gene in chronic thromboembolic pulmonary hypertension.

Authors:  Shinya Amano; Koichiro Tatsumi; Nobuhiro Tanabe; Yasunori Kasahara; Katsushi Kurosu; Yuichi Takiguchi; Yoshitoshi Kasuya; Sadao Kimura; Takayuki Kuriyama
Journal:  Respirology       Date:  2004-06       Impact factor: 6.424

8.  Iloprost improves endothelial barrier function in lipopolysaccharide-induced lung injury.

Authors:  Anna A Birukova; Tinghuai Wu; Yufeng Tian; Angelo Meliton; Nicolene Sarich; Xinyong Tian; Alan Leff; Konstantin G Birukov
Journal:  Eur Respir J       Date:  2012-07-12       Impact factor: 16.671

9.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

Review 10.  Lipid mediators in immune dysfunction after severe inflammation.

Authors:  James N Fullerton; Alastair J O'Brien; Derek W Gilroy
Journal:  Trends Immunol       Date:  2013-11-21       Impact factor: 16.687

View more
  5 in total

1.  Arctigenin Ameliorates Inflammation by Regulating Accumulation and Functional Activity of MDSCs in Endotoxin Shock.

Authors:  Hui Shi; Guanjun Dong; Fenglian Yan; Hui Zhang; Chunxia Li; Qun Ma; Junfeng Zhang; Zhaochen Ning; Zhihua Li; Jun Dai; Jiankuo Ming; Runping Fang; Chuanping Si; Huabao Xiong
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

2.  Lipopolysaccharide-Induced Acute Lung Injury Is Associated with Increased Ran-Binding Protein in Microtubule-Organizing Center (RanBPM) Molecule Expression and Mitochondria-Mediated Apoptosis Signaling Pathway in a Mouse Model.

Authors:  Xiaojing Lv; Xiaomin Lu; Jiping Zhu; Qian Wang
Journal:  Med Sci Monit       Date:  2020-07-18

3.  The urinary lipid profile in cats with idiopathic cystitis.

Authors:  Shinya Takenouchi; Yui Kobayashi; Tatsuya Shinozaki; Koji Kobayashi; Tatsuro Nakamura; Tomohiro Yonezawa; Takahisa Murata
Journal:  J Vet Med Sci       Date:  2022-04-05       Impact factor: 1.105

Review 4.  Potential mouse models of coronavirus-related immune injury.

Authors:  Fu-Yao Nan; Cai-Jun Wu; Jia-Hui Su; Lin-Qin Ma
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

Review 5.  Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review.

Authors:  Oskar Puk; Aleksandra Nowacka; Klaudia Smulewicz; Katarzyna Mocna; Wiktor Bursiewicz; Natalia Kęsy; Justyna Kwiecień; Michał Wiciński
Journal:  Biomed Pharmacother       Date:  2021-12-25       Impact factor: 6.529

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.